Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination

Launched by UNIVERSITY OF ZURICH · May 30, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring how well people who have been fully vaccinated against measles, mumps, and rubella (MMR) are protected against these diseases, especially after receiving a booster shot. The researchers want to understand how immunity changes over time and how effective the booster is in increasing protection.

To be eligible for this study, participants need to be between 18 and 49 years old and have already received two doses of an MMR vaccine within the last year. They must also be willing to receive a booster shot and attend all study visits where they will provide samples like blood and saliva. If you are healthy, not currently pregnant, and meet these criteria, you might be a good fit for this trial. Participants will help improve our understanding of vaccine effectiveness and contribute to public health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18-49 (inclusive) at the time of the study screening visit
• • Has received exactly two previous doses of MMR-containing vaccine at any point up to one calendar year prior to the study screening visit
• • Willing to receive a booster MMR vaccination as outlined in the study protocol
• • Able and willing to comply with all other study requirements (attend all study visits and provide blood, saliva, nasal wash samples at each visit as outlined)
• • Sufficient language (German or English) and cognitive skills
• • Provides written, informed consent to participate in the study
• Exclusion Criteria:
• • Acute respiratory or other infections (postpone baseline visit until resolved)
• • Receipt of any other vaccination less than 4 weeks prior to the baseline visit or intention to receive another vaccination within 4 weeks following the baseline visit
• • Previous hypersensitivity reaction following receipt of any MMR-containing vaccine or previous hypersensitivity reaction to any component of M-M-R-vaxPro
• • Pregnancy, lactation, or intention to become pregnant during the study
• • Individuals with confirmed or suspected immunosuppressive or immune-deficient state
• • Known current or chronic or severe disease
• • Receipt of blood or plasma transfusions, or administration of immune globulin (IG) less than 12 weeks prior to the baseline visit, or intention to receive IG within 4 weeks following the baseline visit
• • Any other significant disease, disorder, or finding which could potentially result in an increased risk to the volunteer due to participation in the study
• • Being enrolled in another interventional study that may interfere with the current study